問題一覧
1
Concentration of the drug at the receptor site.
2
II
3
Less safe
4
Lorazepam is more potent than diazepam.
5
Picrotoxin is a non competitive antagonist.
6
Chemical antagonism
7
AOTA
8
High molecular weight drugs diffuse across cell membrane more easily than low molecular weight drugs.
9
albumin
10
Drugs that are highly bound to plasma proteins generally have a greater VD compared with drugs that are highly bound to tissue proteins.
11
Decreased absorption
12
Class 3
13
I, II & III
14
I & IV
15
Phase 1
16
Acetylation
17
Glucuronosyltransferase
18
I & IV
19
II & III
20
I only
21
GFR
22
Vesamicol
23
Botox
24
Alpha 2
25
Beta 2
26
Phenylephrine
27
Xerostomia
28
Edrophonium
29
Tachycardia
30
Physostigmine
31
Cholinergic
32
NE
33
facilitation of transmitter release
34
V
35
Fenoldopam
36
Stage 1
37
Primary HTN
38
Nadolol
39
Labetalol
40
Amlodipine
41
Captopril
42
ARBs do not inhibit the breakdown of bradykinin.
43
Methyldopa
44
Hydralazine
45
Loop diuretics
46
Chlorthalidone
47
Spironolactone
48
Furosemide
49
Cardiac glycosides
50
AOTA
51
I & III
52
Enoxaparin
53
aPTT
54
Aspirin
55
Dabigatran
56
HMG-CoA Reductase inhibitors
57
upregulation of HMG-CoA reductase
58
Pravastatin
59
l & V
60
II
61
Doxepine
62
Thioridazine
63
First statement is correct
64
Levodopa and carbidopa
65
I & III
66
III only
67
Gold
68
Hypothyroidism
69
Methimazole
70
Propylthiouracil (PTU)
71
Insulin Glargine
72
regular insulin
73
UTI
74
Flatulence
75
Torsemide
76
Saxagliptin
77
Sulfonylureas
78
Exenatide
79
Human chorionic gonadotropin (hCG)
80
Pioglitazone: competitively blocks the binding of estrogens to their receptor
81
Raloxifene: ovulation induction
82
II, & III
83
I & III
84
Cardiovascular thrombotic events
85
Probenecid
86
Fexofenadine
87
Zileuton
88
Betamethasone
89
Latanoprost
90
Alprostadil
91
Magnesium hydroxide
92
Alosetron
93
Extravasation
94
Arsenic
95
EDTA
96
Penicillamine
97
Formic acid
98
Flumazenil
99
Hydroxocobalamin
100
NAPQI
Module 2 Part 1
Module 2 Part 1
ユーザ名非公開 · 100問 · 1年前Module 2 Part 1
Module 2 Part 1
100問 • 1年前Module 1
Module 1
ユーザ名非公開 · 13問 · 1年前Module 1
Module 1
13問 • 1年前Module 2
Module 2
ユーザ名非公開 · 100問 · 1年前Module 2
Module 2
100問 • 1年前Antibiotics
Antibiotics
ユーザ名非公開 · 10問 · 1年前Antibiotics
Antibiotics
10問 • 1年前Module 2 Part 2
Module 2 Part 2
ユーザ名非公開 · 100問 · 1年前Module 2 Part 2
Module 2 Part 2
100問 • 1年前Module 2 (Part 2)
Module 2 (Part 2)
ユーザ名非公開 · 100問 · 1年前Module 2 (Part 2)
Module 2 (Part 2)
100問 • 1年前Module 2 Part 3
Module 2 Part 3
ユーザ名非公開 · 85問 · 1年前Module 2 Part 3
Module 2 Part 3
85問 • 1年前Module 4
Module 4
ユーザ名非公開 · 100問 · 1年前Module 4
Module 4
100問 • 1年前Module 4 Part 2
Module 4 Part 2
ユーザ名非公開 · 100問 · 1年前Module 4 Part 2
Module 4 Part 2
100問 • 1年前Module 4 Part 3
Module 4 Part 3
ユーザ名非公開 · 60問 · 1年前Module 4 Part 3
Module 4 Part 3
60問 • 1年前Module 2 (Part 4)
Module 2 (Part 4)
ユーザ名非公開 · 68問 · 1年前Module 2 (Part 4)
Module 2 (Part 4)
68問 • 1年前Randome Questions
Randome Questions
ユーザ名非公開 · 13問 · 1年前Randome Questions
Randome Questions
13問 • 1年前1
1
ユーザ名非公開 · 100問 · 1年前1
1
100問 • 1年前Module 2 (Part 5)
Module 2 (Part 5)
ユーザ名非公開 · 100問 · 1年前Module 2 (Part 5)
Module 2 (Part 5)
100問 • 1年前2
2
ユーザ名非公開 · 100問 · 1年前2
2
100問 • 1年前Module 2 (Part 6)
Module 2 (Part 6)
ユーザ名非公開 · 68問 · 1年前Module 2 (Part 6)
Module 2 (Part 6)
68問 • 1年前Module 4 Part 1
Module 4 Part 1
ユーザ名非公開 · 5問 · 1年前Module 4 Part 1
Module 4 Part 1
5問 • 1年前問題一覧
1
Concentration of the drug at the receptor site.
2
II
3
Less safe
4
Lorazepam is more potent than diazepam.
5
Picrotoxin is a non competitive antagonist.
6
Chemical antagonism
7
AOTA
8
High molecular weight drugs diffuse across cell membrane more easily than low molecular weight drugs.
9
albumin
10
Drugs that are highly bound to plasma proteins generally have a greater VD compared with drugs that are highly bound to tissue proteins.
11
Decreased absorption
12
Class 3
13
I, II & III
14
I & IV
15
Phase 1
16
Acetylation
17
Glucuronosyltransferase
18
I & IV
19
II & III
20
I only
21
GFR
22
Vesamicol
23
Botox
24
Alpha 2
25
Beta 2
26
Phenylephrine
27
Xerostomia
28
Edrophonium
29
Tachycardia
30
Physostigmine
31
Cholinergic
32
NE
33
facilitation of transmitter release
34
V
35
Fenoldopam
36
Stage 1
37
Primary HTN
38
Nadolol
39
Labetalol
40
Amlodipine
41
Captopril
42
ARBs do not inhibit the breakdown of bradykinin.
43
Methyldopa
44
Hydralazine
45
Loop diuretics
46
Chlorthalidone
47
Spironolactone
48
Furosemide
49
Cardiac glycosides
50
AOTA
51
I & III
52
Enoxaparin
53
aPTT
54
Aspirin
55
Dabigatran
56
HMG-CoA Reductase inhibitors
57
upregulation of HMG-CoA reductase
58
Pravastatin
59
l & V
60
II
61
Doxepine
62
Thioridazine
63
First statement is correct
64
Levodopa and carbidopa
65
I & III
66
III only
67
Gold
68
Hypothyroidism
69
Methimazole
70
Propylthiouracil (PTU)
71
Insulin Glargine
72
regular insulin
73
UTI
74
Flatulence
75
Torsemide
76
Saxagliptin
77
Sulfonylureas
78
Exenatide
79
Human chorionic gonadotropin (hCG)
80
Pioglitazone: competitively blocks the binding of estrogens to their receptor
81
Raloxifene: ovulation induction
82
II, & III
83
I & III
84
Cardiovascular thrombotic events
85
Probenecid
86
Fexofenadine
87
Zileuton
88
Betamethasone
89
Latanoprost
90
Alprostadil
91
Magnesium hydroxide
92
Alosetron
93
Extravasation
94
Arsenic
95
EDTA
96
Penicillamine
97
Formic acid
98
Flumazenil
99
Hydroxocobalamin
100
NAPQI